Last reviewed · How we verify
TEV-56248
TEV-56248 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4.
TEV-56248 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4. Used for Migraine prevention.
At a glance
| Generic name | TEV-56248 |
|---|---|
| Also known as | - fluticasone propionate/albuterol sulfate multidose dry powder inhaler with e-module (Fp/ABS eMDPI) |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | sodium-activated potassium channel inhibitor |
| Target | KCNN4 |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting KCNN4, TEV-56248 is expected to reduce the excitability of neurons and potentially alleviate symptoms associated with certain neurological disorders. However, the exact mechanism of action and therapeutic effects of TEV-56248 are still being investigated in clinical trials.
Approved indications
- Migraine prevention
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
- A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (PHASE3)
- Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |